This article was originally published in The Tan Sheet
Second quarter sales decline 24% to $1.4 mil. due to lower Zicam Allergy Relief revenues resulting from "high level of inventory held by retailers" prior to Q2 and "substantial introductory sales recorded in 2000," company announces Aug. 14. Sales for first six months increased 60% to $7.8 mil. from year-ago period. Phoenix-based firm reports Q2 net loss of $2.3 mil., citing "significant impact" due to settlement, legal costs due to patent infringement lawsuit brought by Quigley (1"The Tan Sheet" June 11, In Brief)
You may also be interested in...
Zicam marketer to pay Quigley $1.1 mil. and 5.5% royalty on cold remedy sales from April 1, 2000 to March 5, 2002, with minimum royalty payment of $500,000, under settlement of Cold-Eeze zinc lozenges marketer's patent infringement lawsuit on fourth day of trial in Philadelphia federal court June 7. Quigley sued Gel Tech in November 1999, alleging Zicam homeopathic zinc nasal spray infringed its '465 patent covering application of zinc gluconate to virus-infected tissue to reduce duration of common cold
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands